What is the difference between myelodysplastic syndromes, myeloproliferative neoplasms, and myelophthisic anemia?

Difference Between Myelodysplasia, Myeloproliferative, and Myelophthisis

These are three fundamentally distinct hematologic entities: myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis with cytopenias and dysplasia; myeloproliferative neoplasms (MPN) are clonal disorders with excessive production of mature blood cells; and myelophthisic anemia is a non-clonal condition caused by physical replacement of bone marrow by infiltrative processes.

Myelodysplastic Syndromes (MDS)

Core Pathophysiology:

• Clonal hematopoietic stem cell disorder with ineffective hematopoiesis 1
• Results in cytopenias (low blood counts) despite typically hypercellular bone marrow 1
• High risk of transformation to acute myeloid leukemia (AML) in approximately one-third of cases 1

Key Diagnostic Features:

• Blood cytopenias with dysplastic changes in ≥2 of 3 cell lineages 2
• Morphologic abnormalities: megaloblastoid erythropoiesis, nucleocytoplasmic asynchrony, dysmorphic megakaryocytes 2
• Variable blast percentage (typically <20%) 1
• Recurrent mutations in genes affecting RNA splicing (SF3B1, SRSF2, U2AF1), epigenetics (TET2, DNMT3A, ASXL1, EZH2), and transcription factors (RUNX1) 3

Clinical Presentation:

• Anemia, thrombocytopenia, and/or neutropenia
• Transfusion dependence common
• Median age ~70 years 1

Myeloproliferative Neoplasms (MPN)

Core Pathophysiology:

• Clonal stem cell disorders with excessive proliferation of mature, functional blood cells 4
• Includes polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)

Key Diagnostic Features:

• Elevated blood counts (erythrocytosis in PV, thrombocytosis in ET) - the opposite of MDS 4
• Driver mutations: JAK2 (most common), CALR, or MPL 4
• Hypercellular marrow with proliferation, not dysplasia
• Risk of thrombohemorrhagic complications 4

Clinical Presentation:

• Thrombosis and bleeding complications
• Splenomegaly
• Constitutional symptoms (pruritus, night sweats)
• Can progress to myelofibrosis or AML 4

Myelophthisic Anemia (Myelophthisis)

Core Pathophysiology:

• Not a clonal disorder - this is the critical distinction
• Physical replacement or infiltration of bone marrow space by abnormal tissue
• Results in secondary bone marrow failure

Causes:

• Metastatic solid tumors (breast, prostate, lung)
• Hematologic malignancies (lymphoma, multiple myeloma)
• Granulomatous disease (tuberculosis, sarcoidosis)
• Storage diseases (Gaucher disease)
• Myelofibrosis (which can be primary MPN or secondary)

Key Diagnostic Features:

• Leukoerythroblastic blood picture: nucleated red blood cells and immature myeloid cells in peripheral blood
• Teardrop cells (dacrocytes) on blood smear
• Bone marrow biopsy shows infiltrative process or fibrosis
• No clonal mutations unless underlying malignancy present

Critical Distinguishing Algorithm

Step 1 - Blood Counts:

• Cytopenias → Consider MDS or myelophthisis
• Elevated counts (especially isolated erythrocytosis or thrombocytosis) → Consider MPN

Step 2 - Peripheral Smear:

• Dysplastic features without leukoerythroblastic picture → MDS
• Leukoerythroblastic picture with teardrop cells → Myelophthisis
• Mature cells without dysplasia → MPN

Step 3 - Bone Marrow:

• Hypercellular with dysplasia → MDS 1
• Hypercellular with proliferation (no dysplasia) → MPN
• Infiltration or replacement → Myelophthisis
• Fibrosis → Primary myelofibrosis (MPN) vs. secondary myelophthisis

Step 4 - Molecular Testing:

• Spliceosome/epigenetic mutations (SF3B1, TET2, ASXL1) → MDS 3
• JAK2/CALR/MPL mutations → MPN 4
• No clonal mutations → Myelophthisis (unless from metastatic malignancy)

MDS/MPN Overlap Syndromes

Important caveat: Some entities have both dysplastic and proliferative features 5, 6:

• Chronic myelomonocytic leukemia (CMML) - most common overlap syndrome
• Atypical CML (BCR-ABL1 negative)
• MDS/MPN with SF3B1 mutation and thrombocytosis
• These require specific WHO classification criteria and often have mixed molecular signatures 6

Common Diagnostic Pitfalls

1. Assuming all cytopenias are MDS: Always exclude myelophthisis with bone marrow biopsy showing architecture
2. Missing overlap syndromes: CMML can present with monocytosis (proliferative) and cytopenias (dysplastic) 5
3. Confusing secondary myelofibrosis with primary: MPN can progress to fibrosis; this is still clonal MPN, not myelophthisis 7
4. Relying solely on morphology: NGS is essential to discriminate MDS from MPN and to identify overlap syndromes 3

The fundamental distinction is that MDS and MPN are clonal stem cell neoplasms (with opposite proliferative patterns), while myelophthisis is non-clonal marrow replacement. Molecular testing definitively separates these entities 3.